HighTower Advisors LLC Boosts Stock Holdings in Insulet Corporation $PODD

HighTower Advisors LLC grew its position in shares of Insulet Corporation (NASDAQ:PODD) by 211.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 7,921 shares of the medical instruments supplier’s stock after purchasing an additional 5,377 shares during the quarter. HighTower Advisors LLC’s holdings in Insulet were worth $2,251,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of PODD. NewEdge Advisors LLC boosted its holdings in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Cresset Asset Management LLC boosted its holdings in shares of Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after buying an additional 177 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after buying an additional 7,030 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after buying an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after buying an additional 791 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Citigroup cut their price target on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday. Benchmark reissued a “buy” rating on shares of Insulet in a report on Wednesday. Canaccord Genuity Group cut their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Stifel Nicolaus cut their price target on shares of Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $252.04.

Insulet Price Performance

PODD opened at $144.94 on Monday. The company has a market capitalization of $10.04 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 1.14 and a beta of 1.13. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $183.55 and a 200-day moving average price of $244.77. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s revenue was up 33.9% on a year-over-year basis. During the same quarter last year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.44 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.